1. 2.6k

    Market Cap circa 128M...

    Initial seed investors holding strong for a $2 share price....

    Althea CEO & Managing Director Josh Fegan added: “Following the strong growth in Q3 FY19 that saw us pass the 500-patient mark, we are very happy to see further acceleration in the growth rate of patients in the first weeks of Q4 FY19. Our team continues to focus on educating Healthcare Professionals about the benefits of Althea’s pharma-grade medicinal cannabis products and providing support to the patients who require them. The ease of use of Althea Concierge has also been a key factor in our success and is complementary to our RACGP and ACRRM accredited medicinal education portal, MEDIC. I look forward to providing the next update on Althea’s increasing uptake soon.”

  2. 2.6k

    AGH progressing....80c in sight

  3. 2.6k

    Should push on.....weed

  4. 2.6k

    Pushed through the $1 Barrier....

    Medicinal Weed on fire

  5. 2.6k

    Another win for AGH.... run should continue

  6. 2.6k

    ASX cannabis share Althea has jumped 535% in less than a year

    ASX share price higher 1.20

    It has been yet another positive day of trade for the Althea Group Holdings Ltd (ASX: AGH) share price.

    In afternoon trade the cannabis company’s shares are up a sizeable 10.5% to a new all-time high of $1.27.

    This latest gain means that Althea’s shares have now gained a remarkable 535% since listing on the ASX at 20 cents per share in September.

    Why is the Althea share price on fire?

    Investors have been snapping up the company’s shares since its IPO thanks to a series of positive developments.

    One major development was the receipt of key manufacture and export licences late last year which mean the company now has a full complement of Office of Drug Control cannabis licences.

    Since then the company has seen its patient numbers grow at a very quick rate. In fact, the company reached its 1,000-patient milestone in Australia five months ahead of schedule.

    But arguably the biggest development has been the company’s successful expansion into the UK market.

    In May the company announced the launch of Althea Concierge UK. This is a medical education platform, which was launched in Australia in September 2018, that provides medical education and clinical evidence for healthcare professionals looking to prescribe medicinal cannabis.

    The platform supports Althea UK’s entry to the market by streamlining the prescription process and facilitating patient referrals from primary care doctors to Althea UK specialist prescribers.

    This led to the company receiving its first patient prescription for Althea medicinal cannabis in the UK last month.

    And it is unlikely to be the last. Also announced last month was an agreement with independent scientific committee Drug Science.

    According to the release, its UK-based business has furthered its relationship with Drug Science with the goal of increasing the number of patients that can be prescribed medical cannabis in the UK market.

    This comes at a time when Drug Science is just about to launch Project TWENTY21, which is the UK’s first national pilot for medical cannabis and aims to enrol 20,000 patients before the end of 2021. Althea looks set to benefit from the pilot as it has been selected to supply, on commercial terms, its range of products to Project TWENTY21.

    Things haven’t been quite so positive for rival AusCann Group Holdings Ltd (ASX: AC8). A lack of meaningful developments has led to its shares shedding 40% of their value since the start of the year.

    But is Althea the best cannabis company to buy right now? You can find out here for free.

    One ASX Stock For An Estimated $US22 Billion Marijuana Market

    A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

    And make no mistake – it is coming. To the tune of an estimated $US22 billion.

    Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

    Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

    AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

  7. 2.6k

    Request for Trading Halt – Althea Group Holdings Limited (ASX: AGH)

    Althea Group Holdings Limited (Althea or the Company) requests the immediate implementation of a
    trading halt in the ordinary shares of the Company, to apply from the commencement of trading on
    22 July 2019 until the commencement of trading on 24 July 2019 (or earlier as set out below).
    For the purpose of ASX Listing Rule 17.1, Althea provides the following information:

    a) The trading halt is requested in connection with an acquisition and capital raise;

    b) Althea requests that the trading halt remain in place until the earlier of Althea making an
    announcement to the market regarding the acquisition and capital raise and the
    commencement of trading on 24 July 2019; and

  8. 2.6k

    Alphea buys into the recreational cannabis market with a 30M CR...

    Investment Highlights:
    • Althea agrees to acquire Canadian extraction and contract manufacturing company Peak Processing Solutions, founded by four former senior personnel from Aphria Inc.
    • Althea has opened one of the UK’s first cannabis destination clinics in central London and plans to open two further clinics in Q3 CY2019
    • In July 2019, Althea received a UK import licence for the first shipment of medicinal cannabis products from Australia
    • Althea is in advanced negotiations regarding a 50/50 joint venture to establish cultivation, extraction and manufacturing (EU GMP) facilities in Portugal
    • Althea has received commitments for a A$30m capital raising to fund the acquisition and further growth initiatives
    25 July 2019: Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’) is pleased to announce that it has agreed to acquire Canadian extraction and contract manufacturing company Peak Processing Solutions (including its freehold interest in a facility in Tecumseh, Ontario Canada) (Peak).
    The Company has also launched one of the UK’s first cannabis destination clinics (MyAccess Clinics) in Belgravia, Central London and intends to open two further clinics under the “MyAccess Clinics” umbrella in Q3 2019.
    The Company received a UK import licence in July 2019 for the first shipment of medicinal cannabis products from Australia. This comes in addition to further patient assessments which are now being conducted within a clearly defined patient access pathway and the proposed sale of products through Boots Pharmacy (approx. 2,500 outlets in the UK).
    Althea has received commitments in a heavily oversubscribed A$30m capital raising from new and existing Institutional shareholders to fund the Peak acquisition and further growth initiatives.
    Peak expected to be a first mover in the cannabis-infused market
    From October 2019, new Canadian cannabis regulations will allow the distribution and sale of cannabis-infused products including edibles, topicals and beverages.
    Peak is an early-stage business set up to operate under the new Canadian regulations and to specialise in extraction, toll processing, and contract manufacturing of cannabis-infused edibles, drinks, nutraceuticals and cosmetics products. In support of its strategy, Peak has applied for one of the industry’s first large-scale (infused) cannabis processor licences (Licence).
    Peak brings with it market leading expertise with four former senior personnel from Aphria Inc (TSX:APHA; NYSE:APHA) who have successfully coordinated the build out of multiple Health Canada approved extraction and manufacturing facilities. The combined cannabis industry experience of the existing Peak team is expected to allow Peak to operate independently of Althea’s existing businesses. The expertise of the Peak personnel will also assist in the growth and expansion of Althea’s medicinal cannabis operations globally.

    Althea considers that Peak is well-positioned to become a leading contract manufacturer for consumer brands looking to launch recreational cannabis and cannabidiol (CBD) wellness products. In addition, expected developments in Peak’s operations (such as product delivery systems and EU-GMP certification) have the potential to enable its facilities to be utilised in the future as part of the Company’s medicinal cannabis products globally.
    Production Capabilities
    Peak’s proposed extraction capabilities span raw cannabis extraction; cannabis extract refinement; cannabinoid isolation of tetrahydrocannabinol (THC), cannabidiol (CBD) and minor cannabinoids; finished goods packaging; cannabinoid potency and quality testing; nano-emulsification; and spray drying. Althea intends that Peak’s facility will be developed and fitted out to include EU-GMP-certified extraction and manufacturing for medicinal cannabis production.
    Acquisition consideration and structure
    Althea’s acquisition of Peak is proposed to proceed by way of Althea (through its wholly owned Canadian subsidiary) acquiring 100% of Peak from Gregg Battersby, a former director of the Company, and 8 employee shareholders of Peak.
    Consideration for the acquisition will predominantly comprise shares in Althea Group Holdings Limited (Shares) with a majority of those shares to be subject to a three-stage performance milestone earn-out. The performance milestones include a combination of consolidated revenue and EBITDA targets.
    On completion of the acquisition, Althea will provide C$4.1m cash (less the amount of any third-party debt held by Peak)1 and 1,331,384 shares to the employee shareholders and 5,502,455 shares to Gregg Battersby2.
    A further 19,018,007 shares will be issued to Gregg Battersby and the employee shareholders subject to the following performance targets:
    1) Performance Target 1 – 5,705,402 Shares upon granting of the Licence.
    2) Performance Target 2 – 5,705,402 Shares if the below conditions are satisfied within 12 months of achieving Performance Target 1:
    o C$7.0m revenue, and
    o C$2.0m EBITDA
    1 Althea will provide Peak with sufficient funds to pay to Gregg Battersby C$973,713.06 of shareholder loans currently owing by Peak of which approximately C$819,000 relate to the acquisition of Peak's facility.
    2 Shares issued to Gregg Battersby will be subject to a mandatory 12-month escrow period under the ASX Listing Rules.
    3) Performance Target 3 - 7,607,203 Shares if the below conditions are satisfied within 18 months of achieving Performance Target 1:
    o C$25.0m revenue, and
    o C$12.5m EBITDA
    Total consideration if all performance targets are met is C$4.1m cash (less the amount of third-party debt) plus 25,851,846 Shares.
    To assist in progressing the Peak business before completion, Althea has provided Peak with a secured C$1.5m working capital facility.
    Conditions and shareholder approval
    Althea’s acquisition of Peak is expected to complete in Q3 CY19 and is conditional on the approval of the Company’s shareholders (including in connection with Gregg Battersby being considered a related party due to his former directorship of the Company), the Company receiving all required ASX or other regulatory waivers and approvals, and the Company receiving from Peak an environmental assessment report regarding its facility in Canada (and the results of that report being acceptable to the Company).
    The Company proposes to issue a Notice of Meeting convening a meeting of the Company's shareholders for the purposes of seeking the required approvals for the transaction shortly. The notice of meeting will include a report from an Independent Expert in relation to the transaction.
    The cash component of the consideration to be paid by Althea on its acquisition of Peak will be funded via a A$30m placement. The placement will be conducted at A$1.00 per new share under our capacity in listing rule 7.1. Total Shares on issue post-transaction will be approximately 233.3million, including the 30million new Shares that will be issued under the placement.
    If the acquisition proceeds, Althea intends to use the funds raised under the placement as follows:

  9. 3

    I can say a little bit about Cbd oils and especially my opinion. These weed tinctures are what I like the most about products that contain marijuana. First of all I heard that they have a medicinal effect and I guess that is a big plus, for sure. I don't really know. However, on your moral state these tinctures influence a lot, relaxing you and making the atmosphere more comfortable. I already take them for a long time fromhttps://www.justcannabis.shopand I'm pleased. I like it when after a more busy day, I rest with the vape in my hand and suddenly I feel with my energy back in me.

  10. 11

    Dads friend Sid does drugs
    I rang police on Sid
    Sid in jail
    Sid don't know I rang police
    Sid said gonna anal who snitched
    I gonna tell Sid was Lisa from down the road

  11. 11

    MulletMan hate drugs

  12. 11

    Thinkin tell Sid that big beard Ned snitched cos Ned mean to MulletMan

Your browser is too old for TopStocks and not secure. Please update your browser